Ubiquitin-dependent activation of NF-κB: K63-linked ubiquitin chains - A link to cancer?

Cancer Biology and Therapy

Volumn 3, Issue 3, 2004, Pages

  Chen, Zhijian J ^a,b   Fuchs, Serge Y ^b  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Cancer; CYLD; E3 ligase; I B; IKK; Kinase; Nemo; NF B; Ubiquitin

Indexed keywords

I KAPPA B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LYSINE; POLYUBIQUITIN; CHUK PROTEIN, HUMAN; I KAPPA B KINASE; IKBKB PROTEIN, HUMAN; IKBKE PROTEIN, HUMAN; PROTEIN SERINE THREONINE KINASE; UBIQUITIN;

CANCER; ENZYME ACTIVATION; ENZYME ACTIVITY; GENE MUTATION; GENE OVEREXPRESSION; GENETIC LINKAGE; HUMAN; MOLECULAR DYNAMICS; NONHUMAN; PROTEIN DEGRADATION; PROTEIN PHOSPHORYLATION; PROTEIN STRUCTURE; REVIEW; SIGNAL TRANSDUCTION; TUMOR GROWTH; UBIQUITINATION; ARTICLE; BIOSYNTHESIS; CELL TRANSFORMATION; DISEASE COURSE; NEOPLASM; PATHOPHYSIOLOGY;

CELL TRANSFORMATION, NEOPLASTIC; DISEASE PROGRESSION; HUMANS; I-KAPPA B KINASE; NEOPLASMS; NF-KAPPA B; PROTEIN-SERINE-THREONINE KINASES; UBIQUITIN;

EID: 25144438691     PISSN: 15384047     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (29)

1. Joyce D, Albanese C, Steer J, Fu M, Bouzahzah B, Pestell RG. NF-κB and cell-cycle regulation: The cyclin connection. Cytokine Growth Factor Rev 2001; 12:73-90.
2. Karin M, Cao Y, Greten FR, Li ZW. NF-kappaB in cancer: From innocent bystander to major culprit. Nat Rev Cancer 2002; 2:301-10.
3. Lin A, Karin M. NF-κB in cancer: A marked target. Semin Cancer Biol 2003; 13:107-14.
4. Ghosh S, Karin M. Missing pieces in the NF-κB puzzle. Cell 2002; 109:581-96.
5. Karin M, Ben-Neriah Y. Phosphorylation meets ubiquitination: The control of NF-κB activity. Annu Rev Immunol 2000; 18:621-63.
6. Chen ZJ, Parent L, Maniatis T. Site-specific phosphorylation of IκBα by a novel ubiquitination-dependent protein kinase activity. Cell 1996; 84:853-62.
7. Deng L, Wang C, Spencer E, et al. Activation of the IκB kinase complex by TRAF6 requires a dimeric ubiquitin-conjugating enzyme complex and a unique polyubiquitin chain. Cell 2000; 103:351-61.
8. Wang C, Deng L, Hong M, Akkaraju GR, Inoue J, Chen ZJ. TAK1 is a ubiquitin-dependent kinase of MKK and IKK. Nature 2001; 412:346-51.
9. Moraes TF, Edwards RA, McKenna S, et al. Crystal structure of the human ubiquitin conjugating enzyme complex, hMms2-hUbc13. Nat Struct Biol 2001; 8:669-73.
10. VanDemark AP, Hofmann RM, Tsui C, Pickart CM, Wolberger C. Molecular insights into polyubiquitin chain assembly: Crystal structure of the Mms2/Ubc13 heterodimer. Cell 2001; 105:711-20.
11. Ninomiya-Tsuji J, Kajino T, Ono K, et al. A resorcylic acid lactone, 5Z-7-oxozeaenol, prevents inflammation by inhibiting the catalytic activity of TAK1 MAPK kinase kinase. J Biol Chem 2003; 278:18485-90.
12. Ishitani T, Takaesu G, Ninomiya-Tsuji J, Shibuya H, Gaynor RB, Matsumoto K. Role of the TAB2-related protein TAB3 in IL-1 and TNF signaling. EMBO J 2003; 22:6277-88.
13. Takaesu G, Surabhi RM, Park KJ, Ninomiya-Tsuji J, Matsumoto K, Gaynor RB. TAK1 is critical for iκB kinase-mediated activation of the NF-κB pathway. J Mol Biol 2003; 326:105-15.
14. Vidal S, Khush RS, Leulier F, Tzou P, Nakamura M, Lemaitre B. Mutations in the Drosophila dTAK1 gene reveal a conserved function for MAPKKKs in the control of rel/NF-κB-dependent innate immune responses. Genes Dev 2001; 15:1900-12.
15. Chen W, White MA, Cobb MH. Stimulus-specific requirements for MAP3 kinases in activating the JNK pathway. J Biol Chem 2002; 277:49105-10.
16. Silverman N, Zhou R, Erlich RL, et al. Immune activation of NF-κB and JNK requires Drosophila TAK1. J Biol Chem 2003; 278:48928-34.
17. Shi CS, Kehrl JH. Tumor necrosis factor (TNF)-induced germinal center kinase-related (GCKR) and stress-activated protein kinase (SAPK) activation depends upon the E2/E3 complex Ubc13-Uev1A/TNF receptor-associated factor 2 (TRAF2). J Biol Chem 2003; 278:15429-34.
18. Trompouki E, Hatzivassiliou E, Tsichritzis T, Farmer H, Ashworth A, Mosialos G. CYLD is a deubiquitinating enzyme that negatively regulates NF-κB activation by TNFR family members. Nature 2003; 424:793-6.
19. Kovalenko A, Chable-Bessia C, Cantarella G, Israel A, Wallach D, Courtois G. The tumour suppressor CYLD negatively regulates NF-κB signalling by deubiquitination. Nature 2003; 424:801-5.
20. Brummelkamp TR, Nijman SM, Dirac AM, Bernards R. Loss of the cylindromatosis tumour suppressor inhibits apoptosis by activating NF-κB. Nature 2003; 424:797-801.
21. Habelhah H, Takahashi S, Cho SG, Kadoya T, Watanabe T, Ronai Z. Ubiquitination and translocation of TRAF2 is required for activation of JNK but not of p38 or NF-κaB. EMBO J 2004; 23:322-32.
22. Yeh WC, Shahinian A, Speiser D, et al. Early lethality, functional NF-κB activation, and increased sensitivity to TNF-induced cell death in TRAF2-deficient mice. Immunity 1997; 7:715-25.
23. Tada K, Okazaki T, Sakon S, et al. Critical roles of TRAF2 and TRAF5 in tumor necrosis factor-induced NF-kappa B activation and protection from cell death. J Biol Chem 2001; 276:36530-4.
24. Legler DF, Micheau O, Doucey MA, Tschopp J, Bron C. Recruitment of TNF receptor 1 to lipid rafts is essential for TNFalpha-mediated NF-κB activation. Immunity 2003; 18:655-64.
25. Huang TT, Wuerzberger-Davis SM, Wu ZH, Miyamoto S. Sequential modification of NEMO/IKKgamma by SUMO-1 and ubiquitin mediates NF-κB activation by genotoxic stress. Cell 2003; 115:565-76.
26. Tang ED, Wang CY, Xiong Y, Guan KL. A role for NF-κB essential modifier/IκB; kinase-γ (NEMO/IKKγ) ubiquitination in the activation of the IκB kinase complex by tumor necrosis factor-α. J Biol Chem 2003; 278:37297-305.
27. Zhou H, Wertz I, O'Rourke K, et al. Bcl10 activates the NF-κB pathway through ubiquitination of NEMO. Nature 2004; 427:167-71.
28. Bignell GR, Warren W, Seal S, et al. Identification of the familial cylindromatosis tumour-suppressor gene. Nat Genet 2000; 25:160-5.
29. Karin M, Yamamoto Y, Wang QM. The IKK NF-κB system: A treasure trove for drug development. Nat Rev Drug Discov 2004; 3:17-26.